Posts
Stomach
cancer is a growth of abnormal tissues that form a tumor in the part of your
abdomen. Symptoms of stomach cancer often include persistent abdominal pain,
extreme heartburn, extreme vomiting, severe indigestion, abdominal swelling,
and frequent diarrhea. These symptoms are common for all forms of stomach
cancer but when cancer spreads to the upper part of the chest, the symptoms
become far more severe and may eventually cause death. Stomach cancer has the
highest survival rate of any type of cancer in the world. Crocetin (trade
name Eulexin) is the first Stomach Cancer Drug that is used in the treatment of
gastric cancer. It was later on approved for treating peritoneal mesothelioma
but was not marketed extensively due to its negative outcomes at the beginning.
Increasing
prevalence of stomach cancer is expected to drive growth of the global stomach
cancer drugs market during the forecast period. According
to the American Cancer Society (ACS), in 2020, around 27,600 new cases of
stomach cancer are expected to be diagnosed in the U.S. According to the World
Cancer Research Fund, in 2018, over 1 million new cases of cancer were
diagnosed across the globe. Stomach cancer is the fourth most commonly
occurring cancer in men and the seventh most commonly occurring cancer in
women. As a result of this, the demand for stomach cancer drugs has increased
significantly worldwide for adequate treatment options. Hence, these factors
are expected to drive growth of the global stomach cancer drugs market during
the forecast period. Moreover, the advent of the novel therapies for metastatic
stomach cancer is expected to boost the global stomach cancer drugs market growth
over the forecast period.
However,
high cost associated with cancer therapy combined with side-effects of cancer
drugs such as appetite loss, diarrhea, anemia, and constipation is expected to
hamper the global stomach cancer drugs market growth over the forecast period.
Among regions, Asia Pacific is expected to witness significant growth in the
global stomach cancer drugs market during the forecast period. This is owing to
the presence of a large patient pool across the region. Moreover, North America
is expected to register a robust growth rate over the forecast period, owing to
the presence of major market players such as Eli, Lily and Company, Merck,
Novartis International AG, F. Hoffmann-La Roche Ltd., and Otsuka Holdings Co.
Ltd.
Major
companies involved in the global stomach cancer drugs market are Bristol-Myers
Squibb, GlaxoSmithKline PLC, Celltrion Inc., Pfizer Inc., Sanofi, Eli, Lily and
Company, Merck, Novartis International AG, F. Hoffmann-La Roche Ltd., and
Otsuka Holdings Co. Ltd.
For instance,
in August 2020, Celltrion Inc. received the World Health Organization (WHO)
prequalification standards for its biosimilar Herzuma indicated for stomach and
breast cancer.
No comments:
Post a Comment